Welcome to the OMA Blog

Denver, CO — February 27, 2026 — The Obesity Medicine Association (OMA) is seeing strong early momentum for its Implementation into Practice Collaborative (IPC), a program designed to help clinicians strengthen obesity care through practical, evidence-based improvements in outpatient settings. It is a reflection of both the diversity of OMA’s membership and our commitment to working together to support every aspect of clinical practice in obesity medicine.” Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP, President of the OTF, D irector of Clinical Education for the OMA The IPC is designed to help clinical teams identify and implement meaningful improvements in obesity care delivery, including workflow redesign, patient-centered treatment approaches, and systems-level strategies that support consistent, high-quality care. OMA expects the collaborative model to accelerate practice transformation, expand access to high-quality obesity care, and help improve health outcomes and quality of life for patients nationwide.

The Obesity Medicine Association (OMA) supports many aspects of the new Dietary Guidelines for Americans , including: A strong emphasis on reducing intake of ultra-processed foods and added sugars A focus on nutrient-dense foods containing fiber, including fruits, vegetables, and whole grains The recommendation to limit saturated fat intake to no more than 10% of total daily calories and to prioritize healthier unsaturated fats Emerging evidence highlighting the importance of nutrition in supporting gut microbiome health Support for extended breastfeeding as beneficial to both maternal and child health At the same time, the OMA emphasizes that obesity is a chronic, relapsing and progressive disease process affecting weight homeostasis.

The Obesity Medicine Association (OMA) is pleased to announce a new multi-phase Quality Improvement (QI) initiative designed to strengthen obesity care delivery across diverse outpatient clinical settings in the United States. OMA is also partnering with Q Synthesis LLC, a healthcare quality improvement company, to develop and implement key components of the initiative. At the heart of the program is the Implementation into Practice Collaborative (IPC) , a virtual learning collaborative that will run from February through May 2026.

The Obesity Medicine Association (OMA) welcomes today’s announcement by the White House Administration regarding expanded access to obesity medications and a commitment to make effective treatment for the chronic disease of obesity more affordable and widely available.

The Trump Administration has announced a proposed plan for a five-year pilot program that will allow patients with Medicare or Medicaid access to anti-obesity medications.

The AMA held its Annual Meeting in Chicago from June 6–11, 2025. I was honored to continue in this role and was joined by our alternate delegate, Dr. Jennifer Paisley. I’d like to share several highlights from this year’s meeting.

The Obesity Medicine Association (OMA) announced its 2025 Award Winners at the recent Obesity Medicine 2025 Conference in National Harbor, MD, this April. ABOM Candidate of the Year Award Presented to the OMA member who scored the highest on the American Board of Obesity Medicine Certification Examination Recipient: Johanna Elizabeth Tran, MD, DABOM The Steelman-Seim Educator Award for Excellence in Academics Recipient: Silvana Pannain, MD Dr.

Dr. Leslie Golden’s journey into obesity medicine was shaped by both personal experience and a deep-rooted passion for improving patient care.

January 27, 2025 – The Obesity Medicine Association (OMA) acknowledges the Lancet Commission’s effort to refine obesity diagnosis with the introduction of “preclinical” and “clinical” obesity classifications. However, we express significant concerns about the potential unintended consequences of this framework, which risks redefining obesity from a disease to merely a risk factor, undermining decades of progress in recognizing obesity as a chronic, progressive and relapsing multifactorial disease.